(19)
(11) EP 1 222 192 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.10.2008 Bulletin 2008/40

(45) Mention of the grant of the patent:
18.06.2008 Bulletin 2008/25

(21) Application number: 00966144.8

(22) Date of filing: 06.10.2000
(51) International Patent Classification (IPC): 
C07D 493/04(2006.01)
A61K 31/36(2006.01)
 A61K 31/34(2006.01)
A61P 31/12(2006.01)
(86) International application number:
PCT/EP2000/009917
(87) International publication number:
WO 2001/025240 (12.04.2001 Gazette 2001/15)

(54)

HEXAHYDROFURO¬2,3-B FURAN-3-YL-N- 3-¬(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR

HEXAHYDROFURO¬2,3-B FURAN-3-YL-N- 3-¬(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMAT ALS RETROVIRUSPROTEASEHEMMER

HEXAHYDROFURO'2,3-B! FURAN-3-YL-N- 3'(1,3-BENZODIOXOL-5-YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL CARBAMATE EN TANT QU'INHIBITEUR DE PROTEASE RETROVIRALE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
LT LV SI

(30) Priority: 06.10.1999 US 157850 P

(43) Date of publication of application:
17.07.2002 Bulletin 2002/29

(73) Proprietors:
  • Tibotec Pharmaceuticals Ltd.
    Eastgate Little Island Co Cork (IE)
  • THE GOVERNMENT OF THE UNITED STATES OF AMERICA,
    MD 20852-3804 (US)

(72) Inventors:
  • WIGERINCK, Piet, Tom, Bert, Paul
    B-2350 Vosselaar (BE)
  • WANG, Guangyang
    Gaihersburg, MD 20879 (US)
  • EISSENSTAT, Michael
    Frederick, MD 21702 (US)
  • ERICKSON, John, W.
    Frederick, MD 21703 (US)

(74) Representative: Daelemans, Frank F.R. 
Tibotec N.V. General De Wittelaan L11 B3
B-2800 Mechelen
B-2800 Mechelen (BE)


(56) References cited: : 
WO-A-94/05639
WO-A-96/33184
WO-A-99/67417
 WO-A-95/06030
WO-A-99/67254
   
  • A. K. GHOSH ET AL.: "Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino]sulfonamide isostere" BIOORG. MED. CHEM. LETT., vol. 8, no. 6, 1998, pages 687-690, XP002156428
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).